By Josh Beckerman
DMK Pharmaceuticals shares more than doubled, to $1.13, Tuesday as the company received a Canadian patent for an opioid intended to treat drug addiction.
Shares are down about 89% this year. The stock closed at 45 cents on Monday.
According to an abstract, the “present invention relates to a method of treating drug addiction and reducing dependence or tolerance on a dependence-inducing opiate drug.”
DMK was known as Adamis Pharmaceuticals until early September. The company sees several potential milestones for its lead clinical stage compound, DPI-125, by the end of 2024, such as the manufacture of a skin-based delivery system and the results of a safety study compared to fentanyl.
Write to Josh Beckerman at josh.beckerman@wsj.com
Read the full article here